Arrillaga-Romany, I., Sahebjam, S., Picconi, D., Campian, J., Giglio, P., Drappatz, J., … Gerstner, E. (2019). A RANDOMIZED PHASE 2 TRIAL OF CEDIRANIB IN COMBINATION WITH OLAPARIB VERSUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. In NEURO-ONCOLOGY (Vol. 21, pp. 27–27). Phoenix, AZ: OXFORD UNIV PRESS INC.

Arrillaga-Romany, Isabel, Solmaz Sahebjam, David Picconi, Jian Campian, Pierre Giglio, Jan Drappatz, Robert Aiken, et al. “A RANDOMIZED PHASE 2 TRIAL OF CEDIRANIB IN COMBINATION WITH OLAPARIB VERSUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA.” In NEURO-ONCOLOGY, 21:27–27. OXFORD UNIV PRESS INC, 2019.

Arrillaga-Romany I, Sahebjam S, Picconi D, Campian J, Giglio P, Drappatz J, et al. A RANDOMIZED PHASE 2 TRIAL OF CEDIRANIB IN COMBINATION WITH OLAPARIB VERSUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2019. p. 27–27.

Arrillaga-Romany, Isabel, et al. “A RANDOMIZED PHASE 2 TRIAL OF CEDIRANIB IN COMBINATION WITH OLAPARIB VERSUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA.” NEURO-ONCOLOGY, vol. 21, OXFORD UNIV PRESS INC, 2019, pp. 27–27.

Arrillaga-Romany I, Sahebjam S, Picconi D, Campian J, Giglio P, Drappatz J, Aiken R, Villano J, Lee E, Welch M, Ellingson B, Ney D, Becker K, Muzikansky A, Das B, Swisher E, Nixon A, Karlovich C, Williams PM, Ivy SP, Batchelor T, Gerstner E. A RANDOMIZED PHASE 2 TRIAL OF CEDIRANIB IN COMBINATION WITH OLAPARIB VERSUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2019. p. 27–27.